|
1
|
Jo SK, Hong JY, Park HJ and Lee SK:
Anticancer activity of novel daphnane diterpenoids from Daphne
genkwa through cell-cycle arrest and suppression of Akt/STAT/Src
signalings in human lung cancer cells. Biomol Ther (Seoul).
20:513–519. 2012. View Article : Google Scholar
|
|
2
|
Wangari-Talbot J and Hopper-Borge E: Drug
resistance mechanisms in non-small cell lung carcinoma. J Can Res
Updates. 2:265–282. 2013.
|
|
3
|
Zhao P, Dai M, Chen W and Li N: Cancer
trends in China. Jpn J Clin Oncol. 40:281–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Wu JZ, Zhang JY, et al: Detection
of circulating vascular endothelial growth factor and matrix
metalloproteinase-9 in non-small cell lung cancer using Luminex
multiplex technology. Oncol Lett. 7:499–506. 2014.PubMed/NCBI
|
|
5
|
Wang S: The promise of cancer therapeutics
targeting the TNF-related apoptosis-inducing ligand and TRAIL
receptor pathway. Oncogene. 27:6207–6215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carswell EA, Old LJ, Kassel RL, Green S,
Fiore N and Williamson B: An endotoxin-induced serum factor that
causes necrosis of tumors. Proc Natl Acad Sci USA. 72:3666–3670.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Old LJ: Tumor necrosis factor (TNF).
Science. 230:630–632. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Roy M, Wielockx B, Baker A and Libert
C: The use of tissue inhibitors of matrix metalloproteinases to
increase the efficacy of a tumor necrosis factor/interferon gamma
antitumor therapy. Cancer Gene Ther. 14:372–379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alexander HR Jr, Bartlett DL and Libutti
SK: Current status of isolated hepatic perfusion with or without
tumor necrosis factor for the treatment of unresectable cancers
confined to liver. Oncologist. 5:416–424. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grunhagen DJ, Brunstein F, ten Hagen TL,
van Geel AN, de Wilt JH and Eggermont AM: TNF-based isolated limb
perfusion: a decade of experience with antivascular therapy in the
management of locally advanced extremity soft tissue sarcomas.
Cancer Treat Res. 120:65–79. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grunhagen DJ, de Wilt JH, ten Hagen TL and
Eggermont AM: Technology insight: Utility of TNF-alpha-based
isolated limb perfusion to avoid amputation of irresectable tumors
of the extremities. Nat Clin Pract Oncol. 3:94–103. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Son KJ, Shin DS, Kwa T, Gao Y and Revzin
A: Micropatterned sensing hydrogels integrated with reconfigurable
microfluidics for detecting protease release from cells. Anal Chem.
85:11893–11901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 27:5287–5297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weng Y, Cai M, Zhu J, et al: Matrix
metalloproteinase activity in early-stage lung cancer. Onkologie.
36:256–259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kao SJ, Su JL, Chen CK, et al: Osthole
inhibits the invasive ability of human lung adenocarcinoma cells
via suppression of NF-κB-mediated matrix metalloproteinase-9
expression. Toxicol Appl Pharmacol. 261:105–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leinonen T, Pirinen R, Bohm J, Johansson
R, Ropponen K and Kosma VM: Expression of matrix metalloproteinases
7 and 9 in non-small cell lung cancer. Relation to
clinicopathological factors, beta-catenin and prognosis. Lung
Cancer. 51:313–321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Siejka A, Barabutis N and Schally AV: GHRH
antagonist inhibits focal adhesion kinase (FAK) and decreases
expression of vascular endothelial growth factor (VEGF) in human
lung cancer cells in vitro. Peptides. 37:63–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shao W, Wang W, Xiong XG, et al:
Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage
IA non-small cell lung cancer. J Surg Oncol. 104:841–846. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qian Q, Wang Q, Zhan P, et al: The role of
matrix metalloproteinase 2 on the survival of patients with
non-small cell lung cancer: a systematic review with meta-analysis.
Cancer Invest. 28:661–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Desmard M, Amara N, Lanone S, Motterlini R
and Boczkowski J: Carbon monoxide reduces the expression and
activity of matrix metalloproteinases 1 and 2 in alveolar
epithelial cells. Cell Mol Biol (Noisy-le-grand). 51:403–408.
2005.
|
|
21
|
Chauhan V, Breznan D, Thomson E,
Karthikeyan S and Vincent R: Effects of ambient air particles on
the endothelin system in human pulmonary epithelial cells (A549).
Cell Biol Toxicol. 21:191–205. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pardo A, Gibson K, Cisneros J, et al:
Up-regulation and profibrotic role of osteopontin in human
idiopathic pulmonary fibrosis. PLoS Med. 2:e2512005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weidner N: Current pathologic methods for
measuring intratumoral microvessel density within breast carcinoma
and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mendolicchio GL and Ruggeri ZM: New
perspectives on von Willebrand factor functions in hemostasis and
thrombosis. Semin Hematol. 42:5–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao C, Qi Y, Chen W, Zhu Y and Chen X:
Effects of IKKɛ on oxidised low-density lipoprotein-induced injury
in vascular endothelial cells. Heart Lung Circ. 22:366–372. 2013.
View Article : Google Scholar
|
|
26
|
Ulger H, Karabulut AK and Pratten MK:
Labelling of rat endothelial cells with antibodies to vWF, RECA-1,
PECAM-1, ICAM-1, OX-43 and ZO-1. Anat Histol Embryol. 31:31–35.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ruggeri ZM: Structure of von Willebrand
factor and its function in platelet adhesion and thrombus
formation. Best Pract Res Clin Haematol. 14:257–279. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai W, Kerner ZJ, Hong H and Sun J:
Targeted cancer therapy with tumor necrosis factor-alpha. Biochem
Insights. 2008:15–21. 2008.PubMed/NCBI
|
|
29
|
Gaughan EM and Costa DB: Genotype-driven
therapies for non-small cell lung cancer: focus on EGFR, KRAS and
ALK gene abnormalities. Ther Adv Med Oncol. 3:113–125. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cooke SP, Pedley RB, Boden R, Begent RH
and Chester KA: In vivo tumor delivery of a recombinant single
chain Fv::tumor necrosis factor-alpha fusion [correction of factor:
a fusion] protein. Bioconjug Chem. 13:7–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
